Peptio

CJC-1295

Also known as CJC-1295 DAC, DAC:GRF

A synthetic analogue of growth hormone-releasing hormone. Two molecules share the name; only one was studied in people, for hormone levels.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary to release growth hormone. It was developed by ConjuChem in the 2000s. It has not been approved as a medicine by FDA or by Australia's TGA, and FDA reports that the developer withdrew it from clinical trials in 2006.

Two molecules, one name

The developer's 2005 paper defines CJC-1295 as a modified 29 amino acid GHRH fragment with an added reactive group that binds albumin in the blood; FDA calls this a drug affinity complex, or DAC. In rats it stayed in the blood for days, though FDA notes that direct evidence is lacking that the DAC group is what prolongs it. Every published human study used that molecule, as FDA reads them.

FDA's December 2024 briefing uses the same name for a different substance: the modified fragment without the DAC group, which it calls CJC-1295, and the developer's molecule, which it calls CJC-1295 DAC. FDA describes them as two different active moieties that are not interchangeable, and states that the pharmacological profile of the DAC version cannot be extrapolated to the version without it. It also states that it found no pharmacological studies of the version without DAC, the substance with a molecular weight of 3367.95. FDA found no study of the version without DAC, which it calls CJC-1295, in people or in animals.

The identifiers on this page are those registries attach to the name CJC-1295: the record at FDA's substance registry, and PubChem's, describe the DAC molecule; the molecular weight of 3647.2 is PubChem's. Neither version can be written in the twenty standard one-letter amino acid codes, because position 2 is a D-amino acid, which is why no sequence is shown.

Where the evidence stands

The human evidence comes from healthy volunteers in 2006 and measured hormones. Two small randomised trials and a study of men before and after one injection showed that the DAC version raises growth hormone and IGF-I for days. A raised hormone level is not an outcome: none of these studies measured muscle, fat, strength, recovery, sleep or ageing.

The one trial in patients, a phase 2 trial in HIV-associated visceral obesity (NCT00267527), is recorded as terminated in 2006, with no reason on the registry and no results.

The animal work shows growth restored in mice lacking their own GHRH and a long-lasting growth hormone response in rats. Neither is a model of a healthy adult using it for fitness or ageing.

FDA and compounding

CJC-1295 is not a component of any FDA-approved drug. In its briefing for the 4 December 2024 Pharmacy Compounding Advisory Committee, FDA evaluated five CJC-1295 substances, with and without DAC, for growth hormone deficiency. It concluded that the studies, conducted in healthy adults and without endpoints such as body composition or height velocity, do not support effectiveness for that condition, and proposed not adding any of them to the 503A Bulks List. At the meeting, the committee, asked whether to place each on the list, voted 0 yes and 13 no for four of them, and 1 yes and 12 no for CJC-1295 acetate. The briefing notes that the nominations had been withdrawn and that FDA was evaluating the substances at its discretion.

FDA's page on compounding safety risks, current as of 22 April 2026, lists CJC-1295 among substances whose nominations were withdrawn, and describes increased heart rate and systemic vasodilatory reaction as serious adverse events associated with it. FDA's 503A list of nominated substances, updated 14 May 2026, does not include CJC-1295 in any category. The documents read for this page do not show a final determination.

What is not known

Whether CJC-1295 has any clinical benefit in people is not known; no trial measuring one has reported. FDA found no study of whether the version without DAC does anything in people, or is safe. Why the patient trial stopped has not been established by any primary source.

Anti-doping

WADA's Prohibited List names CJC-1295 under S2.2.4, growth hormone releasing factors, prohibited at all times; the list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients (source). Earlier second-hand accounts agree. FDA's 2024 briefing states that growth hormone and growth hormone secretagogues, including CJC-1295, are listed as prohibited at all times on WADA's list, and a 2010 anti-doping laboratory paper describes CJC-1295 as prohibited under section S2.

What the research shows

Each statement below is labelled with the strongest kind of study supporting it, and links to that study.

  • Human randomised trialSupportive / Low confidence

    In healthy adults, the version with DAC raised blood levels of growth hormone and IGF-I for days after a single injection, compared with placebo.

    Two randomised, placebo-controlled, double-blind ascending-dose trials, lasting 28 and 49 days, enrolled healthy adults aged 21 to 61. After a single injection, mean plasma growth hormone rose 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9 to 11 days, in a dose-dependent way. The estimated half-life was 5.8 to 8.1 days. After multiple doses, mean IGF-I stayed above baseline for up to 28 days.

    Tested in humans under randomised, controlled conditions.

    • These are hormone levels. The trials measured no muscle, fat, strength, recovery, sleep or ageing outcome.
    • FDA's reading of the full paper: growth hormone exposure rose significantly against placebo only in the 60, 125 and 250 mcg/kg groups, and IGF-I exceeded the age- and sex-adjusted normal range only at 250 mcg/kg.
    • FDA treats the molecule studied as CJC-1295 with DAC, and states that its profile cannot be extrapolated to the molecule without DAC, which is a different active substance.
    • Healthy volunteers, short trials. The figures come from the published abstract only.

    PMID 16352683fda-pcac-cjc1295-briefing-2024

  • Human case reportSupportive / Low confidence

    In healthy men, one injection of the version with DAC raised baseline growth hormone while the normal pulses of release continued.

    Healthy men aged 20 to 40 had overnight blood sampling every 20 minutes before and one week after a single injection. The frequency and size of growth hormone pulses were unchanged, while trough growth hormone rose 7.5-fold, mean growth hormone 46% and IGF-I 45%.

    One or a few individual cases. Cannot show whether an effect is general.

    • No control group: each man was compared with himself before the injection.
    • A hormone pattern, not an outcome.
    • The figures come from the published abstract only.

    PMID 17018654

  • Animal researchSupportive / Low confidence

    In mice lacking their own growth hormone-releasing hormone, CJC-1295 restored normal body weight and length in the most often treated group, and enlarged the pituitary's growth hormone-producing cell population.

    One-week-old GHRH knockout mice were treated for five weeks in three groups that differed in how often they received the same dose. The most often treated group reached normal body weight and length; the other two grew more than placebo-treated mice without full normalisation. Relative lean mass and subcutaneous fat mass were normal in all treated groups. CJC-1295 also increased total pituitary RNA and growth hormone mRNA, which the authors read as proliferation of the somatotroph cells that make growth hormone.

    Observed in animals. Animal results frequently fail to replicate in humans.

    • Mice with a specific genetic growth hormone deficiency, not adults with normal hormone function.

    PMID 16822960

  • Animal researchSupportive / Low confidence

    In rats, the developer's long-acting version gave a larger growth hormone response than the unmodified hormone fragment and stayed in the blood for days.

    In the developer's paper, CJC-1295 showed a 4-fold increase in growth hormone area under the curve over 2 hours compared with hGRF(1-29) in male rats, and was present in plasma beyond 72 hours; a separate analysis found it bound to serum albumin.

    Observed in animals. Animal results frequently fail to replicate in humans.

    • Rats. First author affiliated with the developer, ConjuChem.
    • FDA notes that direct evidence is lacking that the albumin-binding group is what prolongs its half-life, and that the amino acid substitutions may also contribute to its stability.

    PMID 15817669fda-pcac-cjc1295-briefing-2024

Reported and theoretical risks

  • Human RCTmoderate

    Injection-site reactions, flushing, headache and changes in heart rate and blood pressure in healthy volunteers

    The trial abstract reports no serious adverse reactions. FDA, reading the full papers for its 2024 advisory committee, reports injection-site reactions in about 70% of volunteers on CJC-1295 with DAC in the first study and in all of them in the second; headache in 63% against 14% on placebo in the first study, and 20 to 80% across dose groups against 50% on placebo in the second; systemic vasodilatory reactions (flushing, warmth and transient hypotension) in 30%; and in the second study flushing in 40% after low-dose and 100% after high-dose injections. FDA also reports that in the single-injection study the authors described a dose-dependent increase in heart rate, and that serious adverse events were not reported in the available clinical studies, which were small, short and in healthy adults. FDA's page on compounding risks, current as of 22 April 2026, describes increased heart rate and systemic vasodilatory reaction as serious adverse events associated with CJC-1295.

  • Anecdoteserious

    A death during the patient trial, reported second hand

    The phase 2 trial in HIV-associated visceral obesity is recorded on ClinicalTrials.gov as terminated in 2006, with no reason given and no results. FDA's briefing describes anecdotal reports that one participant had chest discomfort two hours after an injection, that an acute myocardial infarction was confirmed, and that the participant died about an hour later. In the same reports, the attending physician gave as the most likely explanation asymptomatic coronary artery disease with plaque rupture and occlusion. FDA also states that the developer withdrew CJC-1295 with DAC from clinical trials in 2006 after a participant's death. Neither FDA nor the registry establishes whether the drug played any part.

  • Mechanismunknown

    No long-term or carcinogenicity data, a genotoxicity signal in cells, and no data at all for the molecule without DAC

    FDA states that it has not identified pharmacological studies of CJC-1295 without DAC, and that the profile of the DAC version cannot be extrapolated to it. For the DAC version, FDA says it remains unknown whether it binds to off-target sites, since the DAC group may bind to thiol groups in proteins other than albumin. FDA states that the long-term safety profile in humans is unknown, that in-vitro experiments in mouse pituitary cells showed a genotoxic signal for the DAC version, and that, without carcinogenicity studies, pituitary hyperplasia and tumours from long-term overstimulation cannot be ruled out. It says there are insufficient data to conclude that CJC-1295 would not raise safety concerns similar to those of approved products that stimulate growth hormone release, whose labels warn of, among others, neoplasm and diabetes. FDA also raises immunogenicity, including possible cross-reactivity with the body's own growth hormone-releasing hormone given 86% homology. In repeat-dose animal studies of the DAC version, it describes injection-site haemorrhage, inflammation and necrosis in rats and dogs.

  • In-vitrounknown

    A seized preparation was not the molecule that was studied

    An unknown preparation submitted by Norwegian police and customs was found by mass spectrometry to contain a 29 amino acid peptide with a C-terminal amide, consistent with a peptide marketed as CJC-1295. FDA reads this as the molecule without DAC, not the one tested in people. FDA calls the inconsistent naming of CJC-1295 substances a safety risk, because patients may receive a different substance from the one ordered.

Regulatory status

Status differs by country and changes over time. Each entry is dated and sourced.

  • USFDAnot approved

    Not approved. In its briefing for the December 2024 Pharmacy Compounding Advisory Committee, FDA proposed not adding any of five CJC-1295 substances, with or without DAC, to the 503A Bulks List of substances pharmacists may compound with. The briefing notes that the nominations were withdrawn and that FDA was evaluating the substances at its discretion.

    As of 4 December 2024. Source

  • USFDAnot approved

    FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists CJC-1295 among substances previously in Category 2 whose nominations were withdrawn by the nominators. Category 2 is a compounding category, not an approval decision.

    As of 22 April 2026. Source

  • AUTGAnot approved

    In a joint statement with Australia's Chief Medical Officer of 19 June 2026, the TGA names CJC-1295 among unapproved peptide products that are not included in the Australian Register of Therapeutic Goods and have not been evaluated by the TGA for safety, quality or effectiveness. The statement was read in a browser by a person on 4 October 2026, because the TGA's website could not be reached from the environment used to research this page.

    As of 19 June 2026. Source

  • internationalWADAbanned in sport

    Named in WADA's Prohibited List under S2.2.4, growth hormone releasing factors, among "growth hormone-releasing hormone (GHRH) and its analogues". Section S2 is prohibited at all times, and its substances are non-Specified. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients; the pasted text does not state the list's year.

    As of 11 October 2026. Source

Research and analysis

  • IpamorelinA synthetic growth hormone secretagogue
  • TesamorelinA growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy

Sources

  1. 1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed 16352683
  2. 2. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: CJC-1295-Related Bulk Drug Substances. U.S. Food and Drug Administration. 2024. View source(open access)
  3. 3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed 17018654
  4. 4. Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American Journal of Physiology. Endocrinology and Metabolism. 2006. PubMed 16822960
  5. 5. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology. 2005. PubMed 15817669
  6. 6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
  7. 7. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov. 2006. NCT00267527(open access)
  8. 8. Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.. Drug Testing and Analysis. 2010. PubMed 21204297
  9. 9. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. View source(open access)
  10. 10. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. View source(open access)